Hypervolemic Hyponatremia in Heart Failure.

Hypervolemic Hyponatremia in Heart Failure. Front Horm Res. 2019;52:113-129 Authors: Davila CD, Udelson JE Abstract Heart failure (HF) represents the most common cause of hypervolemic hyponatremia in current clinical practice. The presence of hyponatremia has been independently associated with worse outcomes in this patient population. The pathogenesis of hyponatremia in HF involves complex neurohormonal and cardio-renal interactions, including an increase in non osmotic secretion of arginine vasopressin (AVP) and insufficient tubular flow in the diluting segments of the nephron. The treatment of hyponatremia in HF involves decongestant therapy with diuretics, neurohormonal blockade and in certain occasions the use of AVP antagonists. The aim of this chapter is to summarize the pathophysiology, current evidence, and management recommendations for hyponatremia in patients with HF, with a specific focus on AVP homeostasis. PMID: 32097923 [PubMed - as supplied by publisher]
Source: Frontiers of Hormone Research - Category: Endocrinology Tags: Front Horm Res Source Type: research

Related Links:

Authors: Ikeya Y, Nakai T, Murata N, Monden M, Ogaku A, Hori K, Watanabe R, Arai M, Okumura Y Abstract To avoid the negative effects associated with pacing, pacemakers are designed to achieve a pacing cadence as close to physiological pacing as possible. In closed-loop stimulation (CLS; a type of rate-responsive functionality used in pacemakers), the changes in impedance (which correlates with the contractility of the myocardium around the lead tip electrode) are tracked, and the paced heart rate is adjusted accordingly. We herein report a case in which we implanted a pacemaker in a post-tricuspid valve replacement...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Objective: To assess the prognostic value of electrocardiographic atrial fibrillation in older hypertensive people in the randomized, placebo-controlled Hypertension in the Very Elderly Trial. Methods: Hypertension in the Very Elderly Trial randomized 3845 hypertensive people aged 80 years and over, 3273 with electrographic data on the presence or absence of atrial fibrillation at baseline and without established cardiovascular disease. Multivariate Cox proportional hazard models were used to estimate hazard ratios with 95% confidence intervals (CIs) for all-cause mortality, incident fatal and nonfatal major cardiovas...
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Risk factors Source Type: research
AbstractHeart transplantation (HT) in patients with prior cardiovascular implantable electronic devices (CIEDs) is becoming more common, in parallel with the increased use of CIEDs for patients with advanced heart failure. Complete removal of CIED components during HT is not always feasible, and it is thus surprising that the literature addressing the implications of retained CIED components is limited. Indeed, there are neither guidelines nor consensus regarding the need for removal of these CIED fragments. This issue is nonetheless becoming important in light of the increase in the percentage of HT candidates having CIED...
Source: Infection - Category: Infectious Diseases Source Type: research
ConclusionsAdjunctive tolvaptan therapy may provide rapid decongestion without a harmful effect on CSNA in ADHF patients with preserved LVEF.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Short Communication Source Type: research
Based on reports from China, we know that most COVID-19 patients (about 80%) will develop mild flulike symptoms, including fever, dry cough, and body aches that can be managed at home. 20% will develop more serious symptoms, such as pneumonia requiring hospitalization, with about a quarter of these requiring ICU-level care. Initial reports focused on the respiratory effects of COVID-19, such as pneumonia and difficulty breathing. But more recent literature has described serious cardiovascular complications occurring in about 10% to 20% of hospitalized patients. Someone with pre-existing heart disease who becomes ill with C...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Heart Health Hypertension and Stroke Infectious diseases Source Type: blogs
Condition:   Acute Heart Failure Intervention:   Drug: Tolvaptan 15 MG Sponsors:   Gia Dinh People Hospital;   Otsuka Pharmaceutical Vietnam Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Heart Failure Intervention:   Other: Exercise with and without Codeine Sponsor:   University of Leeds Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Acute Heart Failure Intervention:   Drug: Tolvaptan 15 MG Sponsors:   Gia Dinh People Hospital;   Otsuka Pharmaceutical Vietnam Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Heart Failure Intervention:   Other: Exercise with and without Codeine Sponsor:   University of Leeds Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Ishida Y, Murayama H, Shinfuku Y, Taniguchi T, Sasajima T, Oyama N Abstract Objectives: The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin is indicated for type 2 diabetes mellitus (T2DM). However, the long-term safety, effectiveness, and clinical relationship with cardiovascular events of vildagliptin have not been evaluated in Japan.Methods: The authors conducted post-marketing surveillance (PMS) to evaluate the safety and effectiveness of vildagliptin in more than 3000 Japanese T2DM patients for up to 3 years. Main assessments included demographics, major adverse cardiovascular events (MACE)...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
More News: Brain | Cardiology | Endocrinology | Heart | Heart Failure | Hormones | Neurology